In conclusion, JNK inhibitors have been proposed as new potential candidates for neurodegenerative diseases, but their lack of specificity and unknown toxicity profile have limited the positive effect of these molecules in clinical trials. Here, MAPK8 is linked to neurodegenerative disease.